Onglyza and Kombiglyze XR
What are Onglyza and Kombiglyze XR?
Onglyza and Kombiglyze XR are an oral diabetes medicines that help control blood sugar levels. They works by regulating the levels of insulin your body produces after eating. Onglyza and Kombiglyze XR are for people with type 2 diabetes and it is sometimes used in combination with other diabetes medications.
Heart Failure and Cancer Risk.
Onglyza (saxagliptin), manufactured by AstraZeneca, was under scrutiny in a study called the SAVOR study. Based on this study, an FDA Advisory Committee recommended a labeling change, which would include information about the potential risk of heart failure and death. Type 2 diabetes patients who take Onglyza may also be at increased risk for specific types of cardiovascular complications, pancreatitis, pancreatic cancer, or thyroid cancer.
FDA Onglyza Warnings.
In 2013, the FDA issued a warning about the possible increased risk of pancreatitis and pancreatic cancer related to Onglyza and other type 2 diabetes drugs. Additionally, in April 2015, an FDA panel agreed that Onglyza should carry a warning about the increased risk of heart failure. This safety alert came after clinical trials linked Onglyza to a 27 percent increased risk of hospitalization for heart failure.
The Time to Pursue a Claim Is Limited. Contact Us Today.
For more information, contact Hissey, Mulderig & Friend today. We offer free, confidential, no obligation consultations. We can help answer your questions, and if you choose to pursue a claim we can connect you with an affiliated attorney who can assist you throughout the legal process.